Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination

Steve Boudewijns, Rutger H T Koornstra, Harm Westdorp, Gerty Schreibelt, Alfons J M van den Eertwegh, Marnix H. Geukes Foppen, John B. Haanen, I. Jolanda M de Vries, Carl G. Figdor, Kalijn F. Bol, Winald R. Gerritsen

Research output: Contribution to journalArticle

Abstract

Background: Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. Methods: Retrospective analysis of 48 stage IV melanoma patients treated with ipilimumab after progression upon DC vaccination earlier in their treatment. DC vaccination was given either as adjuvant treatment for stage III disease (n = 18) or for stage IV disease (n = 30). Ipilimumab (3 mg/kg) was administered every 3 weeks for up to 4 cycles. Results: Median time between progression upon DC vaccination and first gift of ipilimumab was 5.4 mo. Progression-free survival (PFS) rates for patients that received ipilimumab after adjuvant DC vaccination, and patients that received DC vaccination for stage IV melanoma, were 35% and 7% at 1 y and 35% and 3% at 2 y, while the median PFS was 2.9 mo and 3.1 mo, respectively. Median overall survival of patients pre-treated with adjuvant DC vaccination for stage III melanoma was not reached versus 8.0 mo (95% CI, 5.2–10.9) in the group pre-treated with DC vaccination for stage IV disease (HR of death, 0.36; p = 0.017). Grade 3 immune-related adverse events occurred in 19% of patients and one death (2%) was related to ipilimumab. Conclusions: Clinical responses to ipilimumab were found in a considerable number of advanced melanoma patients with progression after adjuvant DC vaccination for stage III disease, while the effect was very limited in patients who showed progression after DC vaccination for stage IV disease.

Original languageEnglish (US)
Article numbere1201625
JournalOncoImmunology
Volume5
Issue number8
DOIs
StatePublished - Aug 2 2016
Externally publishedYes

Fingerprint

Dendritic Cells
Melanoma
Vaccination
Disease-Free Survival
ipilimumab
Gift Giving
Survival Rate
Survival
Therapeutics

Keywords

  • Dendritic cell vaccination
  • immunotherapy
  • ipilimumab
  • melanoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Boudewijns, S., Koornstra, R. H. T., Westdorp, H., Schreibelt, G., van den Eertwegh, A. J. M., Geukes Foppen, M. H., ... Gerritsen, W. R. (2016). Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. OncoImmunology, 5(8), [e1201625]. https://doi.org/10.1080/2162402X.2016.1201625

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. / Boudewijns, Steve; Koornstra, Rutger H T; Westdorp, Harm; Schreibelt, Gerty; van den Eertwegh, Alfons J M; Geukes Foppen, Marnix H.; Haanen, John B.; de Vries, I. Jolanda M; Figdor, Carl G.; Bol, Kalijn F.; Gerritsen, Winald R.

In: OncoImmunology, Vol. 5, No. 8, e1201625, 02.08.2016.

Research output: Contribution to journalArticle

Boudewijns, S, Koornstra, RHT, Westdorp, H, Schreibelt, G, van den Eertwegh, AJM, Geukes Foppen, MH, Haanen, JB, de Vries, IJM, Figdor, CG, Bol, KF & Gerritsen, WR 2016, 'Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination', OncoImmunology, vol. 5, no. 8, e1201625. https://doi.org/10.1080/2162402X.2016.1201625
Boudewijns S, Koornstra RHT, Westdorp H, Schreibelt G, van den Eertwegh AJM, Geukes Foppen MH et al. Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. OncoImmunology. 2016 Aug 2;5(8). e1201625. https://doi.org/10.1080/2162402X.2016.1201625
Boudewijns, Steve ; Koornstra, Rutger H T ; Westdorp, Harm ; Schreibelt, Gerty ; van den Eertwegh, Alfons J M ; Geukes Foppen, Marnix H. ; Haanen, John B. ; de Vries, I. Jolanda M ; Figdor, Carl G. ; Bol, Kalijn F. ; Gerritsen, Winald R. / Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. In: OncoImmunology. 2016 ; Vol. 5, No. 8.
@article{09f87248b40c49609aad9e1ec9975f92,
title = "Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination",
abstract = "Background: Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. Methods: Retrospective analysis of 48 stage IV melanoma patients treated with ipilimumab after progression upon DC vaccination earlier in their treatment. DC vaccination was given either as adjuvant treatment for stage III disease (n = 18) or for stage IV disease (n = 30). Ipilimumab (3 mg/kg) was administered every 3 weeks for up to 4 cycles. Results: Median time between progression upon DC vaccination and first gift of ipilimumab was 5.4 mo. Progression-free survival (PFS) rates for patients that received ipilimumab after adjuvant DC vaccination, and patients that received DC vaccination for stage IV melanoma, were 35{\%} and 7{\%} at 1 y and 35{\%} and 3{\%} at 2 y, while the median PFS was 2.9 mo and 3.1 mo, respectively. Median overall survival of patients pre-treated with adjuvant DC vaccination for stage III melanoma was not reached versus 8.0 mo (95{\%} CI, 5.2–10.9) in the group pre-treated with DC vaccination for stage IV disease (HR of death, 0.36; p = 0.017). Grade 3 immune-related adverse events occurred in 19{\%} of patients and one death (2{\%}) was related to ipilimumab. Conclusions: Clinical responses to ipilimumab were found in a considerable number of advanced melanoma patients with progression after adjuvant DC vaccination for stage III disease, while the effect was very limited in patients who showed progression after DC vaccination for stage IV disease.",
keywords = "Dendritic cell vaccination, immunotherapy, ipilimumab, melanoma",
author = "Steve Boudewijns and Koornstra, {Rutger H T} and Harm Westdorp and Gerty Schreibelt and {van den Eertwegh}, {Alfons J M} and {Geukes Foppen}, {Marnix H.} and Haanen, {John B.} and {de Vries}, {I. Jolanda M} and Figdor, {Carl G.} and Bol, {Kalijn F.} and Gerritsen, {Winald R.}",
year = "2016",
month = "8",
day = "2",
doi = "10.1080/2162402X.2016.1201625",
language = "English (US)",
volume = "5",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination

AU - Boudewijns, Steve

AU - Koornstra, Rutger H T

AU - Westdorp, Harm

AU - Schreibelt, Gerty

AU - van den Eertwegh, Alfons J M

AU - Geukes Foppen, Marnix H.

AU - Haanen, John B.

AU - de Vries, I. Jolanda M

AU - Figdor, Carl G.

AU - Bol, Kalijn F.

AU - Gerritsen, Winald R.

PY - 2016/8/2

Y1 - 2016/8/2

N2 - Background: Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. Methods: Retrospective analysis of 48 stage IV melanoma patients treated with ipilimumab after progression upon DC vaccination earlier in their treatment. DC vaccination was given either as adjuvant treatment for stage III disease (n = 18) or for stage IV disease (n = 30). Ipilimumab (3 mg/kg) was administered every 3 weeks for up to 4 cycles. Results: Median time between progression upon DC vaccination and first gift of ipilimumab was 5.4 mo. Progression-free survival (PFS) rates for patients that received ipilimumab after adjuvant DC vaccination, and patients that received DC vaccination for stage IV melanoma, were 35% and 7% at 1 y and 35% and 3% at 2 y, while the median PFS was 2.9 mo and 3.1 mo, respectively. Median overall survival of patients pre-treated with adjuvant DC vaccination for stage III melanoma was not reached versus 8.0 mo (95% CI, 5.2–10.9) in the group pre-treated with DC vaccination for stage IV disease (HR of death, 0.36; p = 0.017). Grade 3 immune-related adverse events occurred in 19% of patients and one death (2%) was related to ipilimumab. Conclusions: Clinical responses to ipilimumab were found in a considerable number of advanced melanoma patients with progression after adjuvant DC vaccination for stage III disease, while the effect was very limited in patients who showed progression after DC vaccination for stage IV disease.

AB - Background: Ipilimumab has proven to be effective in metastatic melanoma patients. The purpose of this study was to determine the efficacy of ipilimumab in advanced melanoma patients who showed progressive disease upon experimental dendritic cell (DC) vaccination. Methods: Retrospective analysis of 48 stage IV melanoma patients treated with ipilimumab after progression upon DC vaccination earlier in their treatment. DC vaccination was given either as adjuvant treatment for stage III disease (n = 18) or for stage IV disease (n = 30). Ipilimumab (3 mg/kg) was administered every 3 weeks for up to 4 cycles. Results: Median time between progression upon DC vaccination and first gift of ipilimumab was 5.4 mo. Progression-free survival (PFS) rates for patients that received ipilimumab after adjuvant DC vaccination, and patients that received DC vaccination for stage IV melanoma, were 35% and 7% at 1 y and 35% and 3% at 2 y, while the median PFS was 2.9 mo and 3.1 mo, respectively. Median overall survival of patients pre-treated with adjuvant DC vaccination for stage III melanoma was not reached versus 8.0 mo (95% CI, 5.2–10.9) in the group pre-treated with DC vaccination for stage IV disease (HR of death, 0.36; p = 0.017). Grade 3 immune-related adverse events occurred in 19% of patients and one death (2%) was related to ipilimumab. Conclusions: Clinical responses to ipilimumab were found in a considerable number of advanced melanoma patients with progression after adjuvant DC vaccination for stage III disease, while the effect was very limited in patients who showed progression after DC vaccination for stage IV disease.

KW - Dendritic cell vaccination

KW - immunotherapy

KW - ipilimumab

KW - melanoma

UR - http://www.scopus.com/inward/record.url?scp=84981709947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981709947&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2016.1201625

DO - 10.1080/2162402X.2016.1201625

M3 - Article

VL - 5

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 8

M1 - e1201625

ER -